Drugs / Trivalent ganglioside vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01141491 | Jun 2010 → Sep 2013 | sarcoma | MabVax Therapeutics, Inc. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent ganglioside vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01141491 ↗ |
| Modality | Vaccine | “a KLH-conjugated ganglioside vaccine targeting GM2, GD2 and GD3” PMID 36215947 ↗ Oct 2022 |
| Route | Subcutaneous | “Patients received 10 subcutaneous injections at Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84” PMID 36215947 ↗ Oct 2022 |